Is there a link between venous and arterial thrombosis? A reappraisal

  • Paolo PrandoniEmail author


Whether there is a link between venous and arterial thrombotic disorders is still a matter of debate. They share common risk factors, such as old age, male sex and obesity. Endothelial dysfunction and inflammation are likely to play a role in determining the simultaneous involvement of the two vascular compartments. Unlike subclinical atherosclerosis, symptomatic complications of atherosclerosis such as myocardial infarction, ischemic stroke and atrial fibrillation are likely to predict the subsequent development of venous thromboembolic (VTE) complications. Patients with VTE, especially those with apparently unprovoked episodes, have a definitely increased risk of subsequent arterial thrombotic disorders. Drugs that reduce the risk of arterial thrombosis are likely to reduce the risk of venous thrombosis and vice versa. In particular, the direct oral anticoagulants have recently been shown to reduce the risk of both vascular disorders. In conclusion, recent evidence provides compelling evidence in support of the link between venous and arterial thrombosis. Future studies are needed to clarify the nature of this association, to assess its extent, and to evaluate its implications for clinical practice.


Venous thromboembolism Deep-vein thrombosis Pulmonary embolism Atherosclerosis Myocardial infarction Ischemic stroke Risk factors Statins Heparin Aspirin Direct oral anticoagulants Residual vein thrombosis 


Compliance with ethical standards

Conflict of interest

The author declares that they have no conflict of interest.


  1. 1.
    Prandoni P, Bilora F, Marchiori A et al (2003) An association between atherosclerosis and venous thrombosis. N Engl J Med 348(15):1435–1441PubMedCrossRefGoogle Scholar
  2. 2.
    Prandoni P, Piovella C, Pesavento R (2012) Venous thromboembolism and arterial complications. Semin Respir Crit Care Med 33(2):205–210PubMedCrossRefGoogle Scholar
  3. 3.
    Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117(1):93–102PubMedCrossRefGoogle Scholar
  4. 4.
    Mahmoodi BK, Cushman M, Anne Næss I et al (2017) Association of traditional cardiovascular risk factors with venous thromboembolism: an individual participant data meta-analysis of prospective studies. Circulation 135(1):7–16PubMedCrossRefGoogle Scholar
  5. 5.
    Roshani S, Lijfering WM, Coppens M et al (2011) Risk factors of arterial cardiovascular complications in patients with prior venous thromboembolism. Neth J Med 69(1):27–30PubMedGoogle Scholar
  6. 6.
    Wattanakit K, Lutsey PL, Bell EJ et al (2012) Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost 108(3):508–515PubMedPubMedCentralGoogle Scholar
  7. 7.
    Gregson J, Kaptoge S, Bolton T et al (2019) Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 4(2):163–173PubMedCrossRefGoogle Scholar
  8. 8.
    Migliacci R, Becattini C, Pesavento R et al (2007) Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica 92(6):812–818PubMedCrossRefGoogle Scholar
  9. 9.
    Mahmoodi BK, Gansevoort RT, Veeger NJ et al (2009) Microalbuminuria and risk of venous thromboembolism. JAMA 301(17):1790–1797PubMedCrossRefGoogle Scholar
  10. 10.
    Simes J, Robledo KP, White HD et al (2018) D-Dimer predicts long-term cause-specific mortality, cardiovascular events, and cancer in patients with stable coronary heart disease. Circulation 138(7):712–723PubMedCrossRefGoogle Scholar
  11. 11.
    Reich LM, Folsom AR, Key NS et al (2006) Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost 4(9):1909–1913PubMedCrossRefGoogle Scholar
  12. 12.
    van der Hagen PB, Folsom AR, Jenny NS et al (2006) Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 4(9):1903–1908PubMedCrossRefGoogle Scholar
  13. 13.
    Småbrekke B, Rinde LB, Hald EM et al (2017) Repeated measurements of carotid atherosclerosis and future risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost 15(12):2344–2351PubMedCrossRefGoogle Scholar
  14. 14.
    Sørensen HT, Horvath-Puho E, Søgaard KK et al (2009) Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 7(4):521–528PubMedCrossRefGoogle Scholar
  15. 15.
    Cavallari I, Morrow DA, Creager MA et al (2018) Frequency, predictors, and impact of combined antiplatelet therapy on venous thromboembolism in patients with symptomatic atherosclerosis. Circulation 137(7):684–692PubMedCrossRefGoogle Scholar
  16. 16.
    Lutsey PL, Norby FL, Alonso A et al (2018) Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the Atherosclerosis Risk in Communities Study. J Thromb Haemost 16(4):670–679PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Prandoni P, Ghirarduzzi A, Prins MH et al (2006) Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 4(9):1891–1896PubMedCrossRefGoogle Scholar
  18. 18.
    Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P (2007) Venous thromboembolism and subsequent hospitalization due to acute arterial cardiovascular events—a 20 year cohort study. Lancet 370(9601):1773–1779PubMedCrossRefGoogle Scholar
  19. 19.
    Spencer FA, Ginsberg JS, Chong A, Alter DA (2008) The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J Thromb Haemost 6(9):1507–1513PubMedGoogle Scholar
  20. 20.
    Klok FA, Mos IC, Broek L et al (2009) Risk of arterial cardiovascular events in patients after pulmonary embolism. Blood 114(8):1484–1488PubMedCrossRefGoogle Scholar
  21. 21.
    Becattini C, Vedovati M, Ageno W, Dentali F, Agnelli G (2010) Incidence of arterial cardiovascular events after venous thromboembolism. A systematic review and a meta-analysis. J Thromb Haemost 8(5):891–897PubMedGoogle Scholar
  22. 22.
    Chang WT, Chang CL, Ho CH, Hong CS, Wang JJ, Chen ZC (2017) Long-term effects of unprovoked venous thromboembolism on mortality and major cardiovascular events. J Am Heart Assoc 6:e005466PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Prandoni P, Lensing AW, Prins MH et al (2015) The impact of residual thrombosis on the long-term outcome of patients with deep venous thrombosis treated with conventional anticoagulation. Semin Thromb Hemost 41(2):133–140PubMedCrossRefGoogle Scholar
  24. 24.
    Kunutsor SK, Seidu S, Khunti K (2017) Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol 4(2):e83–e93PubMedCrossRefGoogle Scholar
  25. 25.
    Simes J, Becattini C, Agnelli G et al (2014) Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 130(13):1062–1071PubMedCrossRefGoogle Scholar
  26. 26.
    Gibson CM, Chi G, Halaby R et al (2017) Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy. Circulation 135(7):648–655PubMedCrossRefGoogle Scholar
  27. 27.
    Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319–1330PubMedCrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  1. 1.Arianna Foundation On AnticoagulationBolognaItaly

Personalised recommendations